Ovid Therapeutics Hits New 52-Week High of $2.37 Amid Market Challenges

Ovid Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 2.37 on March 10, 2026. This achievement marks a notable point for the microcap company, which operates within the Pharmaceuticals & Biotechnology industry. Despite the recent uptick in stock price, Ovid Therapeutics has experienced a challenging year, with a one-year performance decline of 31.29%, contrasting sharply with the S&P 500's gain of 20.78%. The company's market capitalization stands at USD 191 million, reflecting its microcap status. Financial metrics indicate that Ovid Therapeutics is currently loss-making, as evidenced by the absence of a price-to-earnings (P/E) ratio. The company also shows a negative return on equity of -70.39% and a debt-to-equity ratio of -0.54, suggesting a complex financial landscape. Additionally, the stock's price-to-book ratio is recorded at 4.28, while it has a dividend yield of 0.00%. This recent high could signal a pivotal moment for Ovid Therapeutics as it navigates its position in the competitive biotechnology sector.